Exact Sciences Corporation (EXAS)
NASDAQ: EXAS · Real-Time Price · USD
56.03
+1.14 (2.08%)
Jan 30, 2025, 4:00 PM EST - Market closed
Exact Sciences Employees
Exact Sciences had 6,600 employees as of December 31, 2023. The number of employees increased by 200 or 3.13% compared to the previous year.
Employees
6,600
Change (1Y)
200
Growth (1Y)
3.13%
Revenue / Employee
$407,928
Profits / Employee
-$32,430
Market Cap
10.37B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 6,600 | 200 | 3.13% |
Dec 31, 2022 | 6,400 | -100 | -1.54% |
Dec 31, 2021 | 6,500 | 1,500 | 30.00% |
Dec 31, 2020 | 5,000 | 890 | 21.65% |
Dec 31, 2019 | 4,110 | 2,133 | 107.89% |
Dec 31, 2018 | 1,977 | 709 | 55.91% |
Dec 31, 2017 | 1,268 | 532 | 72.28% |
Dec 31, 2016 | 736 | 59 | 8.71% |
Dec 31, 2015 | 677 | 441 | 186.86% |
Dec 31, 2014 | 236 | 134 | 131.37% |
Dec 31, 2013 | 102 | 15 | 17.24% |
Dec 31, 2012 | 87 | 26 | 42.62% |
Dec 31, 2011 | 61 | 26 | 74.29% |
Dec 31, 2010 | 35 | 16 | 84.21% |
Dec 31, 2009 | 19 | 15 | 375.00% |
Dec 31, 2008 | 4 | -10 | -71.43% |
Dec 31, 2007 | 14 | -8 | -36.36% |
Dec 31, 2006 | 22 | -27 | -55.10% |
Dec 31, 2005 | 49 | -22 | -30.99% |
Dec 31, 2004 | 71 | -11 | -13.41% |
Dec 31, 2003 | 82 | 7 | 9.33% |
Dec 31, 2002 | 75 | 7 | 10.29% |
Dec 31, 2001 | 68 | 24 | 54.55% |
Dec 31, 2000 | 44 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
EXAS News
- 9 days ago - Exact Sciences Demonstrates Leadership in Cancer Innovation with New Data on Screening and Molecular Residual Disease at 2025 ASCO GI Symposium - Business Wire
- 9 days ago - New Evidence Validates Oncodetect's™ Ability to Detect Molecular Residual Disease and Predict Recurrence in Colorectal Cancer Patients - Business Wire
- 17 days ago - Exact Sciences Sparks Analyst Optimism Amid Competitive Multi-Cancer Test Market - Benzinga
- 17 days ago - Exact Sciences Announces Preliminary Fourth Quarter 2024 Results - Business Wire
- 4 weeks ago - Exact Sciences to Participate in J.P. Morgan Healthcare Conference - Business Wire
- 7 weeks ago - AAPA Awarded Grant from Exact Sciences to Improve Colorectal Cancer Screening Rates - GlobeNewsWire
- 2 months ago - Exact Sciences Corporation (EXAS) Annual Evercore ISI HealthCONx Healthcare Conference (Transcript) - Seeking Alpha
- 2 months ago - Exact Sciences Corporation (EXAS) Citi's 2024 Global Healthcare Conference (Transcript) - Seeking Alpha